A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems

Inclusion criteria applicable to all participants * Male or female participants * Age 18-79 years (inclusive) * Body Mass Index (BMI) of 18.5 to 35 kilogram per square meter (kg/m2) (inclusive) * Signed and dated written informed consent in accordance with Guideline for Guideline for Good Clinical Practice - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial * Male participants are not required to use contraception * Women of childbearing potential are allowed to participate provided they use a highly effective contraception from at least 30 days before the administration of trial medication until 7 days after trial completion. Of note, oral hormonal contraceptives are not considered as highly effective in this study due to the potential CYP3A induction by BI 1015550. Methods of contraception considered adequate for female participants of childbearing potential are listed in the protocol. Inclusion criteria applying only to participants with impaired hepatic function * Hepatic impairment classified as Child-Pugh A (score 5-6 points) or Child-Pugh B (score 7-9 points) * further inclusion criteria apply Inclusion criteria applying only to participants with normal hepatic function * Individually matched to participants with hepatic impairment according to sex, age, and weight * further inclusion criteria apply Exclusion criteria applying to all participants * Any evidence of a concomitant disease assessed as clinically relevant by the i…